Is ARQT a Buy? What to Consider in 2026
Short answer
The bull case for Arcutis Biotherapeutics (ARQT) rests on Multi-indication ZORYVE expansion: ZORYVE has moved from a single plaque-psoriasis cream to a franchise spanning psoriasis, seborrheic dermatitis, and atopic dermatitis across creams and a foam. 2026 revenue guidance is ~$480-495 million. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The dominant risk is single-product concentration: nearly all revenue depends on ZORYVE, so any slowdown in prescriptions, an unfavorable payer or pricing shift, a safety signal, or eventual generic and patent challenges would hit the whole company. Whether ARQT is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on medical dermatology. Its business is built around ZORYVE, a topical formulation of roflumilast that inhibits phosphodiesterase type 4 (PDE4), an anti-inflammatory target long used in dermatology. ZORYVE is sold as a cream 0.3% for plaque psoriasis, a foam 0.3% for seborrheic dermatitis, and cream formulations (0.15% and 0.05%) for atopic dermatitis spanning adults down to young children. The pitch to dermatologists is a steroid-free, once-daily topical with a clean tolerability profile that can be used on sensitive and intertriginous skin, and the company markets it as the leading branded topical across those three inflammatory skin conditions combined. The investment picture is a classic single-franchise growth story reaching an inflection. ZORYVE net product sales grew to about $372 million in 2025, up roughly 123% year over year, and Arcutis posted its first profitable quarter in Q4 2025 with positive operating cash flow before guiding 2026 revenue to roughly $480 to $495 million. Because nearly all revenue comes from one molecule, the stock is highly sensitive to prescription momentum, payer coverage, gross-to-net pricing dynamics, and new-indication approvals (including pediatric and infant atopic dermatitis expansions). Profitability is not yet consistent (Q1 2026 slipped back to a small loss on seasonal patterns and reinvestment), and the company still carries a large accumulated deficit from its pre-commercial years, so results can stay volatile even as the top line compounds.
What's the case for buying ARQT?
1. Multi-indication ZORYVE expansion
ZORYVE has moved from a single plaque-psoriasis cream to a franchise spanning psoriasis, seborrheic dermatitis, and atopic dermatitis across creams and a foam. Each new FDA-approved indication and each step down in age (now into young children, with an infant atopic dermatitis filing) widens the addressable prescriber base off one familiar molecule. This multi-indication strategy is the core engine behind roughly 90%-plus annual revenue growth.
2. Revenue growth reaching profitability
Net product sales grew to about $372 million in 2025, and the company reported net income of roughly $17 million in Q4 2025 with positive operating cash flow, its first profitable quarter. Management guided 2026 revenue to roughly $480 to $495 million. Reaching self-funded profitability would reduce reliance on dilutive financing and mark a durable shift from cash-burning launch mode.
3. Payer coverage and prescriber reach
A large part of the growth has come from expanding commercial and Medicare coverage plus an enlarged dermatology sales force targeting higher-volume prescribers. Broader formulary access lowers patient out-of-pocket cost and improves the gross-to-net economics that turn prescriptions into recognized revenue. Continued coverage wins and better prescriber call frequency are key levers for converting demand into reported sales.
4. Pipeline and label depth
Beyond current approvals, Arcutis is pursuing further ZORYVE label expansions (younger pediatric psoriasis and infant atopic dermatitis) and evaluating additional roflumilast and dermatology assets. Guideline recommendations from dermatology bodies support adoption. This gives the franchise a longer runway, though the pipeline remains concentrated around a single mechanism rather than a broadly diversified portfolio.
What are the risks to ARQT?
The dominant risk is single-product concentration: nearly all revenue depends on ZORYVE, so any slowdown in prescriptions, an unfavorable payer or pricing shift, a safety signal, or eventual generic and patent challenges would hit the whole company. Profitability is early and inconsistent, with Q1 2026 returning to a small loss on seasonality and reinvestment, and the business carries a large accumulated deficit built up over its pre-commercial years. Competition is real, including Incyte's Opzelura (a JAK-inhibitor cream), Dermavant's Vtama (tapinarof), generic topical steroids, and systemic biologics like Dupixent in atopic dermatitis. Gross-to-net adjustments, rebates, and inventory timing can make quarterly revenue lumpy, and continued sales-force and marketing spend can keep operating results volatile even as demand grows.
How is ARQT valued? (as of MAY 2026)
Snapshot for ARQT as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- ZORYVE net sales (FY2025): ~$372 million (+123% YoY)
- 2026 revenue guidance: ~$480-495 million
- Q4 2025 revenue: ~$128 million (+84% YoY)
- Q4 2025 net income: ~$17 million (first profitable quarter)
- FY2025 net loss: ~$16 million
- Cash and investments: ~$200 million
- Market cap: ~$3 billion
As of MAY 2026, Arcutis trades as a high-growth, single-franchise dermatology name rather than a stable earner, so its valuation leans on ZORYVE's revenue trajectory and the durability of its early profitability. With a market cap near $3 billion against roughly $372 million of 2025 sales, the price-to-sales multiple reflects growth expectations, and the stock is sensitive to any change in prescription momentum or guidance. Because full-year GAAP profitability is not yet consistent, trailing P/E is not a meaningful anchor.
How do you decide if ARQT is a buy?
Rather than asking whether ARQT is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ARQT indirectly through an index or sector ETF before adding more.
For the full picture, see the ARQT stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ARQT against your real portfolio and see your actual exposure before deciding.
The bottom line on ARQT
The bottom line: Arcutis Biotherapeutics's story right now is Multi-indication ZORYVE expansion, with 2026 revenue guidance at ~$480-495 million. If you believe that narrative continues, the call is about sizing ARQT sensibly and checking overlap with what you own; if you doubt it (the risk: the dominant risk is single-product concentration: nearly all revenue depends on ZORYVE, so any slowdown in prescriptions, an unfavorable payer or pricing shift, a safety signal, or eventual generic and patent challenges would hit the whole company.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around ARQT with Walnut
Use Arcutis Biotherapeutics as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is ARQT a good stock to buy right now?
+
The case for Arcutis Biotherapeutics right now is Multi-indication ZORYVE expansion, with 2026 revenue guidance at ~$480-495 million. If you believe that thesis holds, ARQT is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the dominant risk is single-product concentration: nearly all revenue depends on ZORYVE, so any slowdown in prescriptions, an unfavorable payer or pricing shift, a safety signal, or eventual generic and patent challenges would hit the whole company. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Arcutis Biotherapeutics do?
+
Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on medical dermatology.
What are the main risks of ARQT?
+
The dominant risk is single-product concentration: nearly all revenue depends on ZORYVE, so any slowdown in prescriptions, an unfavorable payer or pricing shift, a safety signal, or eventual generic and patent challenges would hit the whole company. Profitability is early and inconsistent, with Q1 2026 returning to a small loss on seasonality and reinvestment, and the business carries a large accumulated deficit built up over its pre-commercial years. Competition is real, including Incyte's Opzelura (a JAK-inhibitor cream), Dermavant's Vtama (tapinarof), generic topical steroids, and systemic biologics like Dupixent in atopic dermatitis. Gross-to-net adjustments, rebates, and inventory timing can make quarterly revenue lumpy, and continued sales-force and marketing spend can keep operating results volatile even as demand grows.
What does Arcutis Biotherapeutics do?
+
Arcutis is a commercial-stage medical dermatology company. Its business centers on ZORYVE, a topical roflumilast (PDE4 inhibitor) sold as creams and a foam approved for plaque psoriasis, seborrheic dermatitis, and atopic dermatitis across a range of ages.
What is ZORYVE and why does it matter to ARQT?
+
ZORYVE is Arcutis's flagship product and the source of essentially all its revenue. It is a steroid-free, once-daily topical PDE4 inhibitor that the company markets as the leading branded topical across three inflammatory skin conditions, so ARQT's results track ZORYVE prescriptions closely.
Is Arcutis profitable?
+
Arcutis reached its first profitable quarter in Q4 2025 (about $17 million net income) with positive operating cash flow, but it still reported a small net loss for full-year 2025 and slipped back to a loss in Q1 2026. Profitability is at an early inflection rather than consistently established.
How fast is Arcutis growing?
+
ZORYVE net sales grew to roughly $372 million in 2025, up about 123% year over year, and management guided 2026 revenue to roughly $480 to $495 million. Growth has been driven by new indications, broader age labels, and expanding payer coverage.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell ARQT; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.